Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003594769 | SCV004244759 | uncertain significance | Familial focal epilepsy with variable foci | 2023-11-13 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 371 of the DEPDC5 protein (p.Glu371Lys). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with DEPDC5-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004978897 | SCV005563438 | uncertain significance | Inborn genetic diseases | 2024-10-17 | criteria provided, single submitter | clinical testing | The c.1111G>A (p.E371K) alteration is located in exon 16 (coding exon 15) of the DEPDC5 gene. This alteration results from a G to A substitution at nucleotide position 1111, causing the glutamic acid (E) at amino acid position 371 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |